AMLX - Amylyx Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$31.50
DETAILS
HIGH:
$40.00
LOW:
$24.00
MEDIAN:
$31.00
CONSENSUS:
$31.50
DOWNSIDE:
10.28%
About Amylyx Pharmaceuticals, Inc. (https://amylyx.com)
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Joshua Cohen | Co-Founder, Co-CEO & Director | 1992 | $1,251,798 USD |
| Justin Klee | Co-CEO & Director | 1991 | $1,251,798 USD |
| Camille L. Bedrosian | Chief Medical Officer | 1953 | $1,007,806 USD |
| James Frates | Chief Financial Officer | 1967 | $817,183 USD |
| Gina Mazzariello | Chief Legal Officer & General Counsel | 1972 | $715,494 USD |
| Linda A. Arsenault | Chief Human Resources Officer | – | – |
| Lindsey Allen | Head of Investor Relations & Communications | – | – |
| Machelle Manuel | Vice President & Head of Global Medical Affairs | – | – |
| Tammy Sarnelli | Global Head of Regulatory Affairs | – | – |
| Tom Holmes | Chief Technical Operations Officer | – | – |